Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.46 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.46 |
| ▸ | CES1 | P23141 | 1/20 | 0.42 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.39 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | TAS2R14 | Q9NYV8 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL160202 | 0.79 | LMNA (0.50) | LMNAGAAKCNK3KCNK9CES1 | |
| SCHEMBL4630453 | 0.78 | CES1 (0.56) | LMNACES1POLB | |
| SCHEMBL28567994 | 0.76 | LMNA (0.47) | LMNAGAAKCNK3KCNK9CES1 | |
| SCHEMBL31369140 | 0.76 | GAA (0.56) | LMNAGAAKCNK3KCNK9CES1 | |
| SCHEMBL3717986 | 0.76 | GAA (0.56) | LMNAGAAKCNK3KCNK9CES1 | |
| SCHEMBL27524184 | 0.74 | LMNA (0.55) | LMNAGAAKCNK3KCNK9CES1 | |
| SCHEMBL3244585 | 0.74 | LMNA (0.53) | LMNAGAAKCNK3KCNK9CNR2 | |
| SCHEMBL2493438 | 0.73 | LMNA (0.57) | LMNAGAAKCNK3KCNK9CNR2 | |
| SCHEMBL221518 | 0.72 | LMNA (0.62) | LMNAGAAKCNK3KCNK9CNR2 | |
| SCHEMBL31319408 | 0.72 | LMNA (0.52) | LMNAGAAKCNK3KCNK9CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4664597-B2 | — | — | 2011-04-06 | — | — | JP | claimed |
| EP-1511734-B1 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2010-06-23 | — | — | EP | claimed |
| US-20090005580-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2009-01-01 | — | — | US | claimed |
| EP-1511734-A4 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS INC (US) | 2006-05-10 | — | — | EP | claimed |
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | CYTOKINETICS, INC. | 2006-01-26 | — | — | US | claimed |
| JP-2005523312-A | — | — | 2005-08-04 | — | — | JP | claimed |
| US-6924376-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2005-08-02 | — | — | US | claimed |
| EP-1511734-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-09 | — | — | EP | claimed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | claimed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-8633236-B2 | Compounds, compositions and methods | CYTOKINETICS, INC. (US) | 2014-01-21 | — | — | US | disclosed |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2013-02-28 | — | — | US | disclosed |
| US-8329928-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-12-11 | — | — | US | disclosed |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | MCDONALD ANDREW (US) | 2012-08-16 | — | — | US | disclosed |
| US-8119678-B2 | Compounds, compositions and methods | CYTOKINETICS, INCORPORATED (US) | 2012-02-21 | — | — | US | disclosed |
| EP-1554265-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | Cytokinetics, Inc. (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1511734-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | Cytokinetics, Inc. (US) | 2005-03-09 | — | — | EP | disclosed |
| US-20040082638-A1 | Compounds, compositions and methods | CYTOKINETICS, INC. | 2004-04-29 | — | — | US | disclosed |
| WO-2004024086-A2 | COMPOUNDS, COMPOSITIONS AND METHODS | CYTOKINETICS, INC. (US) | 2004-03-25 | — | — | WO | disclosed |
| WO-2003088903-A2 | COMPOUNDS, COMPOSITIONS, AND METHODS | CYTOKINETICS, INC. (US) | 2003-10-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060020008-A1 | Treating cell proliferation disorder, anticancer agents | MKI67, PCNA, TK1 | LMNA 2572/4885GAA 292/4885KCNK3 3154/4885 |
| US-20040082638-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | LMNA 568/4885GAA 367/4885KCNK3 2721/4885 |
| US-20090005580-A1 | Compounds, compositions and methods | ALPP, PCNA, MKI67 | LMNA 568/4885GAA 367/4885KCNK3 2721/4885 |
| US-20120209012-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | LMNA 568/4885GAA 367/4885KCNK3 2721/4885 |
| US-20130053436-A1 | COMPOUNDS, COMPOSITIONS AND METHODS | ALPP, PCNA, MKI67 | LMNA 568/4885GAA 367/4885KCNK3 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.